Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
78
CPRX Quote, Financials, Valuation and Earnings
Last price:
$22.07
Seasonality move
:
14.72%
Day range:
$20.99 - $21.84
52-week range:
$14.47 - $24.64
Dividend yield:
0%
P/E ratio:
16.65x
P/S ratio:
5.54x
P/B ratio:
3.64x
Volume:
1.2M
Avg. volume:
1.1M
1-year change:
35.72%
Market cap:
$2.6B
Revenue:
$491.7M
EPS (TTM):
$1.31
Analysts' Opinion
-
Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $33.33, Catalyst Pharmaceuticals has an estimated upside of 52.84% from its current price of $21.81.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing 100% downside risk from its current price of $21.81.
Fair Value
-
According to the consensus of 7 analysts, Catalyst Pharmaceuticals has 52.84% upside to fair value with a price target of $33.33 per share.
CPRX vs. S&P 500
-
Over the past 5 trading days, Catalyst Pharmaceuticals has overperformed the S&P 500 by 4.11% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Catalyst Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Catalyst Pharmaceuticals has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Catalyst Pharmaceuticals reported revenues of $141.8M.
Earnings Growth
-
Catalyst Pharmaceuticals has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Catalyst Pharmaceuticals reported earnings per share of $0.44.
Enterprise value:
2.1B
EV / Invested capital:
2.93x
Price / LTM sales:
5.54x
EV / EBIT:
10.92x
EV / Revenue:
4.33x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
8.91x
Price / Operating cash flow:
11.39x
Enterprise value / EBITDA:
9.15x
Gross Profit (TTM):
$422.9M
Return On Assets:
23.78%
Net Income Margin (TTM):
33.33%
Return On Equity:
27.81%
Return On Invested Capital:
27.81%
Operating Margin:
44.31%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $214.2M | $398.2M | $491.7M | $110.6M | $141.8M | |
| Gross Profit | $179.8M | $346.2M | $422.9M | $94.8M | $120.2M | |
| Operating Income | $101.8M | $86.8M | $195.1M | $41.7M | $62.8M | |
| EBITDA | $103.1M | $119.7M | $232.9M | $50.8M | $72.3M | |
| Diluted EPS | $0.74 | $0.61 | $1.31 | $0.31 | $0.44 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $159.2M | $210.1M | $320.8M | $219.3M | $623.6M | |
| Total Assets | $192.4M | $237.8M | $375.6M | $470.1M | $851.4M | |
| Current Liabilities | $22.8M | $27.1M | $57.6M | $76.1M | $120.7M | |
| Total Liabilities | $22.8M | $31M | $75.2M | $82.2M | $123.8M | |
| Total Equity | $169.6M | $206.8M | $300.4M | $387.9M | $727.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $116M | $143.6M | $239.8M | $55.6M | $70.9M | |
| Cash From Investing | $9.2M | -$293.5M | -$556K | -$38.3M | -$88K | |
| Cash From Financing | $1.7M | -$10.9M | $140.7M | -$665K | $4.4M | |
| Free Cash Flow | $116M | $61.9M | $239.3M | $53.3M | $70.8M | |
CPRX
Sector
Market Cap
$2.6B
$37.4M
Price % of 52-Week High
88.52%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
-5.58%
-0.75%
1-Year Price Total Return
35.72%
-38.36%
Beta (5-Year)
0.836
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$21.42
200-day SMA
Buy
Level
$19.99
Bollinger Bands (100)
Sell
Level
21.17 - 22.81
Chaikin Money Flow
Buy
Level
4.1M
20-day SMA
Sell
Level
$21.87
Relative Strength Index (RSI14)
Buy
Level
50.23
ADX Line
Buy
Level
13.62
Williams %R
Neutral
Level
-52.3379
50-day SMA
Sell
Level
$22.17
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
270.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.7402)
Buy
CA Score
(Annual)
Level (2.7381)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-6.875)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Stock Forecast FAQ
In the current month, CPRX has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CPRX average analyst price target in the past 3 months is $33.33.
-
Where Will Catalyst Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Catalyst Pharmaceuticals share price will rise to $33.33 per share over the next 12 months.
-
What Do Analysts Say About Catalyst Pharmaceuticals?
Analysts are divided on their view about Catalyst Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Catalyst Pharmaceuticals is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Catalyst Pharmaceuticals's Price Target?
The price target for Catalyst Pharmaceuticals over the next 1-year time period is forecast to be $33.33 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CPRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Catalyst Pharmaceuticals is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CPRX?
You can purchase shares of Catalyst Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Catalyst Pharmaceuticals shares.
-
What Is The Catalyst Pharmaceuticals Share Price Today?
Catalyst Pharmaceuticals was last trading at $22.07 per share. This represents the most recent stock quote for Catalyst Pharmaceuticals. Yesterday, Catalyst Pharmaceuticals closed at $21.81 per share.
-
How To Buy Catalyst Pharmaceuticals Stock Online?
In order to purchase Catalyst Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
